Verve Therapeutics Secures $94M in Series B Financing

Verve Therapeutics

Verve Therapeutics, a Cambridge, Mass.-based biotech company pioneering gene editing medicines to treat cardiovascular disease, closed a $94m Series B financing.

The round was led by Wellington Management Company and co-led by Casdin Capital with participation from Redmile Group, Janus Henderson Investors, Cormorant Asset Management, Rock Springs Capital, Novo Holdings A/S, Logos Capital, Surveyor Capital (a Citadel company), RA Capital Management, GV and Biomatics.

The company intends to use the funds to advance its pipeline of gene editing medicines, led by VERVE-101, and further extend its scientific and technical leadership.

Led by Sekar Kathiresan, M.D., chief executive officer, Verve isis a biotechnology company developing VERVE-101, comprised of a messenger RNA for adenine base editing and a guide RNA for PCSK9 gene targeting, packaged in a lipid nanoparticle delivery vehicle, for the initial treatment of heterozygous familial hypercholesterolemia (HeFH), a potentially fatal genetic heart disease.